(BANB) Bachem Holding - SW
Sector: Healthcare | Industry: Biotechnology | Exchange: SW (Switzerland) | Market Cap: 4.998m CHF | Total Return: 19.3% in 12m
Avg Turnover: 10.4M
Warnings
No concerns identified
Tailwinds
Confidence
Bachem Holding AG, headquartered in Bubendorf, Switzerland, specializes in the development and manufacturing of peptide and oligonucleotide active pharmaceutical ingredients (APIs). The company provides a comprehensive range of services to the global pharmaceutical and biotechnology sectors, including research-grade production, clinical development support, and commercial-scale manufacturing of new chemical entities (NCEs) and generic drugs.
The company operates within the specialized Contract Development and Manufacturing Organization (CDMO) market, where high barriers to entry exist due to the complex chemical synthesis required for long-chain peptides. Unlike standard commodity chemicals, peptide manufacturing requires stringent adherence to Good Manufacturing Practice (GMP) standards and significant regulatory oversight to ensure product purity for therapeutic use.
To evaluate how these manufacturing capabilities translate into long-term financial performance, consider reviewing the detailed valuation metrics available on ValueRay.
- Peptide and oligonucleotide manufacturing capacity expansion drives long-term revenue growth
- GLP-1 drug demand accelerates commercial scale peptide production volume
- High capital expenditure on new facilities impacts short-term free cash flow
- Strategic shift toward large-scale oligonucleotide production diversifies product portfolio
| Net Income: 148.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA 4.30 > 1.0 |
| NWC/Revenue: 46.23% < 20% (prev 89.52%; Δ -43.29% < -1%) |
| CFO/TA 0.13 > 3% & CFO 271.4m > Net Income 148.8m |
| Net Debt (26.7m) to EBITDA (179.8m): 0.15 < 3 |
| Current Ratio: 1.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (75.0m) vs 12m ago -0.02% < -2% |
| Gross Margin: 28.74% > 18% (prev 30.16%; Δ -1.43% > 0.5%) |
| Asset Turnover: 34.48% > 50% (prev 31.48%; Δ 3.01% > 0%) |
| Interest Coverage Ratio: 289.7 > 6 (EBIT TTM 140.2m / Interest Expense TTM 484k) |
| A: 0.15 (Total Current Assets 726.8m - Total Current Liabilities 405.5m) / Total Assets 2.11b |
| B: 0.43 (Retained Earnings 917.1m / Total Assets 2.11b) |
| C: 0.07 (EBIT TTM 140.2m / Avg Total Assets 2.02b) |
| D: 2.24 (Book Value of Equity 1.46b / Total Liabilities 650.4m) |
| Altman-Z'' = 5.24 = AAA |
| DSRI: 0.60 (Receivables 188.2m/273.3m, Revenue 695.1m/605.3m) |
| GMI: 1.05 (GM 30.16% / 28.74%) |
| AQI: 1.19 (AQ_t 0.02 / AQ_t-1 0.02) |
| SGI: 1.15 (Revenue 695.1m / 605.3m) |
| TATA: -0.06 (NI 148.8m - CFO 271.4m) / TA 2.11b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of June 20, 2026, the stock is trading at CHF 67.95 with a total of 468,066 shares traded.
Over the past week, the price has changed by +2.88%,
over one month by -11.87%,
over three months by +10.09% and
over the past year by +19.31%.
Bachem Holding has no consensus analysts rating.
P/E Trailing = 33.6869
P/E Forward = 28.3286
P/S = 7.1909
P/B = 3.4479
P/EG = 0.6112
Revenue TTM = 695.1m CHF
EBIT TTM = 140.2m CHF
EBITDA TTM = 179.8m CHF
Long Term Debt = 70.0k CHF (from longTermDebtTotal, last quarter)
Short Term Debt = 57.3m CHF (from shortTermDebt, last quarter)
Debt = 57.7m CHF (from shortLongTermDebtTotal, last quarter) + Leases 290k
Net Debt = 26.7m CHF (calculated: Debt 57.7m - CCE 31.0m)
Enterprise Value = 5.02b CHF (5.00b + Debt 57.7m - CCE 31.0m)
Interest Coverage Ratio = 289.7 (Ebit TTM 140.2m / Interest Expense TTM 484k)
EV/FCF = -104.2x (Enterprise Value 5.02b / FCF TTM -48.2m)
FCF Yield = -0.96% (FCF TTM -48.2m / Enterprise Value 5.02b)
FCF Margin = -6.93% (FCF TTM -48.2m / Revenue TTM 695.1m)
Net Margin = 21.41% (Net Income TTM 148.8m / Revenue TTM 695.1m)
Gross Margin = 28.74% ((Revenue TTM 695.1m - Cost of Revenue TTM 495.3m) / Revenue TTM)
Gross Margin QoQ = 28.70% (prev 28.77%)
Tobins Q-Ratio = 2.38 (Enterprise Value 5.02b / Total Assets 2.11b)
Interest Expense / Debt = 0.84% (Interest Expense 484k / Debt 57.7m)
Taxrate = 4.86% (7.61m / 156.4m)
NOPAT = 133.4m (EBIT 140.2m * (1 - 4.86%))
Current Ratio = 1.79 (Total Current Assets 726.8m / Total Current Liabilities 405.5m)
Debt / Equity = 0.04 (Debt 57.7m / totalStockholderEquity, last quarter 1.46b)
Debt / EBITDA = 0.15 (Net Debt 26.7m / EBITDA 179.8m)
Debt / FCF = -0.55 (negative FCF - burning cash) (Net Debt 26.7m / FCF TTM -48.2m)
Total Stockholder Equity = 1.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.38% (Net Income 148.8m / Total Assets 2.11b)
RoE = 10.79% (Net Income TTM 148.8m / Total Stockholder Equity 1.38b)
RoCE = 10.17% (EBIT 140.2m / Capital Employed (Equity 1.38b + L.T.Debt 70.0k))
RoIC = 7.71% (NOPAT 133.4m / Invested Capital 1.73b)
WACC = 8.78% (E(5.00b)/V(5.06b) * Re(8.87%) + D(57.7m)/V(5.06b) * Rd(0.84%) * (1-Tc(0.05)))
Discount Rate = 8.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 53.94 | Cagr: 2.05%
[DCF] Fair Price = unknown (Cash Flow -48.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 96.77 | Revenue CAGR: 10.97% | SUE: 0.06 | # QB: 0
EPS current Year (2026-12-31): EPS=2.38 | Chg30d=-3.73% | Revisions=+20% | GrowthEPS=+20.3% | GrowthRev=+37.1%
EPS next Year (2027-12-31): EPS=3.00 | Chg30d=-0.90% | Revisions=+64% | GrowthEPS=+25.8% | GrowthRev=+20.9%
[Analyst] Revisions Ratio: +64%